Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ecolab pty ltd - non-ionic detergents; sodium hydroxide - liquid - non-ionic detergents emulsifiers & surfactants-noni active 6.0 g/l; sodium hydroxide mineral-sodium-base active 644.0 g/l - dairy cleanser - milking equipment | milking machine - residue, dirt in milking equipment

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ecolab pty ltd - non-ionic detergents; sodium hydroxide - soluble powder - non-ionic detergents emulsifiers & surfactants-noni active 9.0 g/kg; sodium hydroxide mineral-sodium-base active 800.0 g/kg - dairy cleanser - dairy equipment stainless steel | dairy plant stainless steel | building - residue, dirt in milking equipment

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ecolab pty ltd - non-ionic detergents; potassium hydroxide - liquid - non-ionic detergents emulsifiers & surfactants-noni active 26.0 g/l; potassium hydroxide mineral-potassium-base other 1.4 g/l - dairy cleanser - dairy equipment stainless steel | dairy plant stainless steel | building - wetting agent (use as directed) | improve penetrating properties

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ecolab pty ltd - non-ionic detergents; phosphoric acid - liquid concentrate - non-ionic detergents emulsifiers & surfactants-noni active 30.0 g/l; phosphoric acid mineral-phosphorus-acid active 1152.0 g/l - dairy cleanser - milking equipment | milking machine - milkstone removal | milk fat | milk protein | mineral deposits

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dubois chemicals australia pty ltd - nonyl phenol ethoxylate; sodium hydroxide - powder - nonyl phenol ethoxylate emulsifiers & surfactants-noni active 10.0 g/kg; sodium hydroxide mineral-sodium-base active 800.0 g/kg - dairy cleanser - dairy equipment - residue, dirt in milking equipment

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ecolab pty ltd - alkaline salts; non-ionic detergents - soluble powder - alkaline salts cleanser/sanitiser active 690.0 g/kg; non-ionic detergents emulsifiers & surfactants-noni active 18.0 g/kg - dairy cleanser - milking equipment | milking machine - residue, dirt in milking equipment

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hydrochloride 150 mg - propafenone hydrochloride tablets are indicated to: - prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms in patients without structural heart disease. - prolong the time to recurrence of paroxysmal supraventricular tachycardia (psvt) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (psvt) associated with disabling symptoms in patients without structural heart disease. - treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. initiate treatment in the hospital. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life

United States - English - NLM (National Library of Medicine)

american health packaging - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hydrochloride 150 mg - propafenone hydrochloride is indicated to: - prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms in patients without structural heart disease. - prolong the time to recurrence of paroxysmal supraventricular tachycardia (psvt) associated with disabling symptoms in patients without structural heart disease. - treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. initiate treatment in the hospital. usage considerations: - the use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (af) or in patients exclusively with atrial flutter or psvt has not been evaluated. do not use propafenone hydrochloride tablets to control ventricular rate during af. - some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. concomitant treatment with drugs that increase the f

United States - English - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hydrochloride 150 mg - propafenone hydrochloride tablets are indicated to: usage considerations: propafenone hydrochloride tablets are contraindicated in the following circumstances: risk summary there are no studies of propafenone hydrochloride tablets in pregnant women. available data from published case reports and several decades of postmarketing experience with use of propafenone hydrochloride tablets in pregnancy have not identified any drug-associated risks of miscarriage, birth defects, or adverse maternal or fetal outcomes. untreated arrhythmias during pregnancy may pose a risk to the pregnant woman and fetus (see clinical considerations) . propafenone and its metabolite, 5-oh-propafenone, cross the placenta in humans. in animal studies, propafenone was not teratogenic. at maternally toxic doses (ranging from 2 to 6 times the maximum recommended human dose [mrhd]), there was evidence of adverse developmental outcomes when administered to pregnant rabbits and rats during organogenesis or when administered to pregnant rat

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hydrochloride 150 mg - propafenone hydrochloride is indicated to: - prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms in patients without structural heart disease. - prolong the time to recurrence of paroxysmal supraventricular tachycardia (psvt) associated with disabling symptoms in patients without structural heart disease. - treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. initiate treatment in the hospital. usage considerations: - the use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (af) or in patients exclusively with atrial flutter or psvt has not been evaluated. do not use propafenone hydrochloride tablets to control ventricular rate during af. - some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. concomitant treatment with drugs that increase the